JUNS — Jupiter Neurosciences, Inc.
$2.98+15.50%
Last close: · regular session
After-hours $2.87 -3.53% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for JUNS in the TickerWise workspace.
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 4
- Website: https://www.jupiterorphan.com
Latest SEC filings for JUNS
Latest JUNS news
- Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson's Disease and Exploration of Strategic Options to Maximize Shareholder Value Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.